Inscription Capital’s Nektar Therapeutics NKTR Stock Holding History

Inscription Capital’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,000	Closed	-$257K	–	335
2021 Q2	$257K	Buy	+1,000	New	+$277K	0.03%	278

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Inscription Capital's NKTR Position: Q3 2021 in Review

Inscription Capital sold out of Nektar Therapeutics (NKTR) in Q3 2021, closing a stake of 1,000 shares — an estimated $257K sold.

Inscription Capital first reported a position in NKTR in Q2 2021 and held it in 1 quarter. The position peaked at $257K in Q2 2021. 240 funds tracked by Wall St. Rank hold NKTR as of Q3 2021.

Inscription Capital reported no remaining Nektar Therapeutics position as of Q3 2021 after selling out during the quarter.
Inscription Capital sold 1,000 Nektar Therapeutics shares in Q3 2021, an estimated $257K.
Inscription Capital first reported a position in Nektar Therapeutics in Q2 2021 and held it in 1 quarter.
Inscription Capital's Nektar Therapeutics position peaked at $257K in Q2 2021.
240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2021.

Based on Inscription Capital's 13F filing for Q3 2021, filed 9 Nov 2021.